替奈普酶静脉溶栓联合血管内治疗用于4.5至24小时缺血性卒中:TNK-PLUS随机临床试验
TNK-PLUS是一项在中国40个中心开展的多中心、3期、随机、开放标签、盲法终点、优效性试验,纳入391例发病4.5至24小时、因大脑中动脉M1或近端M2闭塞且存在可挽救脑组织的成人急性缺血性卒中患者。患者按1:1随机接受血管内治疗前静脉替奈普酶0.25 mg/kg(最大剂量25 mg)或单纯血管内治疗。90天功能独立(改良Rankin量表0-2分)在替奈普酶组为44.2%,单纯血管内治疗组为43.2%(调整相对率1.01,95%CI 0.83-1.24;P=0.89;风险差0.99%,95%CI -8.84%至10.83%)。90天死亡率分别为12.7%和14.2%,36小时内症状性颅内出血分别为5.1%和2.6%。
要点
- 发病4.5至24小时、大脑中动脉M1或近端M2闭塞且存在可挽救脑组织的成人患者,血管内治疗前静脉替奈普酶未改善90天功能独立(44.2% vs 43.2%;调整相对率1.01,95%CI 0.83-1.24;P=0.89)。
- 90天死亡在替奈普酶组为12.7%(25/197),单纯血管内治疗组为14.2%(27/190)。
- 36小时内症状性颅内出血在替奈普酶组为5.1%(10/197),单纯血管内治疗组为2.6%(5/190)。
- 静脉替奈普酶剂量为0.25 mg/kg,最大剂量25 mg,在血管内治疗前给药。
- 该试验为多中心、3期、随机、开放标签、盲法终点、优效性试验,共纳入391例患者。
适用人群与场景
- 年龄≥18岁的成人急性缺血性卒中患者,发病4.5至24小时(最后已知正常时间起算)。
- 因大脑中动脉M1或近端M2闭塞所致,且CT灌注或MR灌注-弥散成像显示存在可挽救脑组织:缺血核心体积<70 mL、不匹配比≥1.8、不匹配体积≥15 mL。
- 研究在具备血管内治疗能力的中心进行。
诊断标准与关键阈值
- 缺血核心体积<70 mL、不匹配比≥1.8、不匹配体积≥15 mL(CT灌注或MR灌注-弥散成像)。
- 改良Rankin量表评分0-2分定义为90天功能独立。
处置流程与药物剂量
- eligible患者按1:1随机接受静脉替奈普酶0.25 mg/kg(最大剂量25 mg)后行血管内治疗,或单纯血管内治疗。
研究设计与关键结果
- 多中心、3期、随机、开放标签、盲法终点、优效性试验,在中国40个中心纳入391例患者(替奈普酶组199例,单纯血管内治疗组192例),全部完成试验。
- 90天功能独立:替奈普酶组88例(44.2%),单纯血管内治疗组83例(43.2%);调整相对率1.01(95%CI 0.83-1.24;P=0.89);风险差0.99%(95%CI -8.84%至10.83%)。
- 90天死亡:替奈普酶组12.7%(25/197),单纯血管内治疗组14.2%(27/190)。
- 36小时内症状性颅内出血:替奈普酶组5.1%(10/197),单纯血管内治疗组2.6%(5/190)。
证据类型、等级与局限
- 证据类型:多中心、3期、随机、开放标签、盲法终点、优效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于发病4.5至24小时、大脑中动脉M1或近端M2闭塞且存在可挽救脑组织的成人患者,血管内治疗前静脉给予替奈普酶0.25 mg/kg(最大剂量25 mg)未改善90天功能独立。
- 原文结论:在此类患者中,血管内治疗前静脉替奈普酶与单纯血管内治疗相比未改善临床结局。
指南或共识出处
- TNK-PLUS随机临床试验(ClinicalTrials.gov标识符NCT06221371)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Whether intravenous tenecteplase prior to endovascular treatment (EVT) for ischemic stroke reduces disability in the late time window is unclear.
OBJECTIVE: To investigate the adverse events and efficacy of tenecteplase prior to EVT in patients 4.5 to 24 hours after ischemic stroke onset due to proximal middle cerebral artery (MCA) occlusion.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, phase 3, randomized, open-label, blinded end point, superiority trial conducted at 40 centers in China. Adult (≥18 years) patients with acute ischemic stroke 4.5 to 24 hours after last known to be well due to MCA-M1 or proximal M2 occlusion with salvageable brain tissue (ischemic core volume <70 mL, mismatch ratio ≥1.8, and mismatch volume ≥15 mL) identified on computed tomography-perfusion or magnetic resonance-perfusion-diffusion imaging were enrolled from January 25, 2024, through July 21, 2025, and followed up for 90 days. Final follow-up occurred on October 14, 2025.
INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous tenecteplase (0.25 mg/kg; maximum dose, 25 mg) before EVT (n = 199) or EVT alone (n = 192).
MAIN OUTCOMES AND MEASURES: The primary outcome was functional independence, defined as a score of 0 to 2 on the modified Rankin Scale (range, 0-6, with higher scores indicating greater disability) at 90 days. Adverse events outcomes included symptomatic intracranial hemorrhage and death.
RESULTS: All of the 391 patients enrolled (median age, 68 years [IQR, 59-75]; 155 [39.6%] females) completed the trial. Functional independence at 90 days occurred in 88 patients (44.2%) in the tenecteplase before EVT group and 83 patients (43.2%) in the EVT alone group (adjusted relative rate, 1.01 [95% CI, 0.83-1.24]; P = .89; risk difference, 0.99% [95% CI, -8.84% to 10.83%]). Mortality within 90 days was 12.7% (25/197) in the tenecteplase before EVT group and 14.2% (27/190) in the EVT alone group. Symptomatic intracranial hemorrhage within 36 hours was 5.1% (10/197) and 2.6% (5/190), respectively.
CONCLUSIONS AND RELEVANCE: In patients presenting to EVT-capable centers 4.5 to 24 hours after stroke onset with proximal MCA occlusion, intravenous tenecteplase before EVT did not improve clinical outcomes vs EVT alone.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06221371.
参考来源
- Xiong Y, Che F, Wang H, et al. Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial. JAMA. 2026. PMID: 42099212. doi:10.1001/jama.2026.4292
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。